OncoImmunology · 2019 · 48 citations · 39 references
Life SciencesImmunologyOncologyCancer ImmunologyMolecular OncologyTumor ImmunologyAntibody CharacterizationAntibody ScreeningAntibody-antigen RecognitionTumor AntigensTumor MarkersTumor-associated AntigensAntigen-specific Antibody DiscoveryImmunoassay BiomarkersOvarian Cancer ImmunologyOvarian Cancer Prognostic BiomarkersSerological ProfilingTumor Antigen DiscoveryTumor Antigen ValidationTumor-specific Antigen Identification
The identification of effective biomarkers for early diagnosis, prognosis, and response to treatments remains a challenge in ovarian cancer (OC) research. Here, we present an unbiased high-throughput approach to profile ascitic fluid autoantibodies in order to obtain a tumor-specific antigen signature in OC. We first reported the reactivity of immunoglobulins (Igs) purified from OC patient ascites towards two different OC cell lines. Using a discovery set of Igs, we selected tumor-specific antigens from a phage display cDNA library. After biopanning, 700 proteins were expressed as fusion protein and used in protein array to enable large-scale immunoscreening with independent sets of cancer and noncancerous control. Finally, the selected antigens were validated by ELISA. The initial screening identified eight antigenic clones: CREB3, MRPL46, EXOSC10, BCOR, HMGN2, HIP1R, OLFM4, and KIAA1755. These antigens were all validated by ELISA in a study involving ascitic Igs from 153 patients (69 with OC, 34 with other cancers and 50 without cancer), with CREB3 showing the highest sensitivity (86.95%) and specificity (98%). Notably, we were able to identify an association between the tumor-associated (TA) antibody response and the response to a first-line tumor treatment (platinum-based chemotherapy). A stronger association was found by combining three antigens (BCOR, CREB3, and MRLP46) as a single antibody signature. Measurement of an ascitic fluid antibody response to multiple TA antigens may aid in the identification of new prognostic signatures in OC patients and shift attention to new potentially relevant targets.
39
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs
Dominik Sturm, Brent A. Orr, Umut H. Toprak et al. · Cell · 2016 · 1K citations · Full text
Medicine, Neurosurgery, Oncology +14
BCoR, a novel corepressor involved in BCL-6 repression
Khanh D. Huynh, Wolfgang Fischle, Eric Verdin et al. · Genes & Development · 2000 · 487 citations · Full text
Diagnostic Markers for Early Detection of Ovarian Cancer
Irene Visintin, Ziding Feng, Gary Longton et al. · Clinical Cancer Research · 2008 · 419 citations
Medicine, Gynecology, Oncology +17
Structure of the large ribosomal subunit from human mitochondria
Alan Brown, Alexey Amunts, Xiao‐chen Bai et al. · Science · 2014 · 334 citations